ArticleRespirology case reports2025
Primary Pulmonary Leiomyosarcoma: A Case of Prolonged Survival With Radiotherapy and Pazopanib in a 90-Year-Old Female.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Primary Pulmonary Leiomyosarcoma: A Case of Prolonged Survival With Radiotherapy and Pazopanib in a 90-Year-Old Female.Respirology case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary pulmonary leiomyosarcoma is an exceedingly rare malignancy, comprising less than 0.5% of all lung cancers. Due to its rarity, no standardised treatment guidelines exist. Prognosis is especially poor in cases which are deemed unresectable. We describe the case of a 90-year-old woman who presented with progressive dyspnea and cough over 1 month. Chest computed tomography revealed a large right hilar mass extending into the right upper and middle lobes, abutting the mediastinum and pericardium. Histopathological analysis confirmed primary pulmonary leiomyosarcoma. Given her advanced age and comorbidities, she was not a candidate for surgical intervention. Molecular profiling demonstrated PDL1 expression < 1% and no targetable mutations, ruling out the option of immunotherapy. She was managed with palliative radiotherapy followed by pazopanib therapy. Serial imaging demonstrated disease control, with an extended survival of approximately 5 years. Despite a median reported survival of 14 months, our patient achieved prolonged survival, highlighting the importance of an individualised therapeutic approach for elderly patients with rare malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.